Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 3 de 3
Filtrer
Plus de filtres











Base de données
Gamme d'année
1.
Ann Card Anaesth ; 27(4): 337-343, 2024 Oct 01.
Article de Anglais | MEDLINE | ID: mdl-39365132

RÉSUMÉ

BACKGROUND: The incidence of hyperlactatemia due to hypoperfusion during cardiopulmonary bypass (CPB) increases morbidity. Carbon dioxide production during CPB is one of the lactate production markers, in addition to other markers such as delivery oxygen (DO2), oxygen consumption (VO2), mixed vein oxygen saturation (SvO2), and oxygen extraction ratio (O2ER). METHOD: This observational analytic study was conducted on 40 adult cardiac surgery patients using a CPB machine. Initial lactate is taken when entering CPB and final lactate is examined 15 min after coming off bypass. The values of DO2, VO2, SvO2, VCO2, respiratory quotient (RQ), DO2/VCO2, PvCO2 × Ve/Q were calculated from the results of blood and venous gas analysis 1 h after entering CPB in the nadir of core temperature and lowest pump flow. RESULT: The multivariate test showed that the value of PvCO2 × Ve/Q was more effective than other oxygenation and carbon dioxide parameters in predicting an increase in the percentage of lactate. Each increase of 1 mmHg PvCO2 ×× Ve/Q can predict a final lactate increase of 29% from the initial lactate. The high PvCO2 × Ve/Q value is also the strongest correlation factor for the incidence of hyperlactatemia after CPB (final lactate >3 mmol/L). The cutoff value of this marker is >19.3 mmHg, which has a sensitivity of 100% and a specificity of 55.6% with a strong correlation value. CONCLUSION: The PvCO2 × Ve/Q value proved to be one of the significant markers in predicting hyperlactatemia during cardiac surgery using CPB.


Sujet(s)
Dioxyde de carbone , Pontage cardiopulmonaire , Hyperlactatémie , Acide lactique , Pression partielle , Humains , Pontage cardiopulmonaire/effets indésirables , Hyperlactatémie/sang , Hyperlactatémie/étiologie , Dioxyde de carbone/sang , Mâle , Femelle , Adulte d'âge moyen , Acide lactique/sang , Sujet âgé , Gazométrie sanguine/méthodes , Consommation d'oxygène/physiologie , Oxygène/sang , Adulte , Procédures de chirurgie cardiaque
2.
Saudi J Anaesth ; 18(1): 70-76, 2024.
Article de Anglais | MEDLINE | ID: mdl-38313701

RÉSUMÉ

Background: Activation of the hypothalamus-pituitary-adrenal (HPA) axis and inflammatory processes are common forms of stress response. The increased stress response is associated with a higher chance of complications. Open hearth surgery is one of the procedures with a high-stress response. Pectointercostal fascial block (PIFB), as a new pain management option in sternotomy, has the potential to modulate the stress response. Objective: To determine the effect of PIFB on stress response in open heart surgery. Methods: This study was a Randomized Controlled Trial on 40 open heart surgery. Patients were divided into two groups, control (20 patients) and PIFB (20 patients). Primary parameters included basal and postoperative TNF-α, basal and post sternotomy ACTH, and basal, 0, and 24 hours postoperative NLR. Secondary parameters include the amount of opioid use, length of the post-operative ventilator, length of ICU stay, and Numeric Rating Scale (NRS) 6, 12, 24, and 48 hours postoperative. Results: The PIFB group had a decrease in ACTH levels with an average change that was not significantly different from the control group (-57.71 ± 68.03 vs. -129.78 ± 140.98). The PIFB group had an average change in TNFα levels and an average increase in NLR 0 hours postoperative that was not significantly lower than the control group (TNFα: -0.52 ± 1.31 vs. 0.54 ± 1.76; NLR: 12.80 ± 3.51 vs. 14.82 ± 4.23). PIFB significantly reduced the amount of opioid use during surgery, NRS at 6, 12, and 24 hours, and the length of post-operative ventilator use (P < 0.05, CI: 95%). Conclusion: PIFB has a good role in reducing the stress response of open heart surgery and producing good clinical outcomes.

3.
J Infect Dev Ctries ; 15(9): 1257-1262, 2021 09 30.
Article de Anglais | MEDLINE | ID: mdl-34669593

RÉSUMÉ

Severe COVID-19 infection management for a recipient of kidney transplant has debatable prognosis and treatment. We described the case of a COVID-19 infected 70 year old female, previously had renal transplantation in 2017. The patient took immunosuppressive agents as routine drugs for transplant recipient status and received lopinavir/ritonavir, hydroxychloroquine, and dexamethasone daily at the hospitalization. Specific question arises about renal transplant recipients being infected by COVID-19 - whether the infection will get worse compared to those without immunosuppresive agent. In this case, author decided to stop the immunosuppressive agent followed administration of combination lopinavir/ritonavir, hydroxychloroquine, and dexamethasone that gives a good clinical impact change to patient's condition after once getting worsened and mechanically ventilated. Nevertheless, the assessment of risk and benefit in continuing immunosuppressive drugs is concurrently essential due to the prevention of transplant rejection.


Sujet(s)
Traitements médicamenteux de la COVID-19 , Dexaméthasone/usage thérapeutique , Hydroxychloroquine/usage thérapeutique , Lopinavir/usage thérapeutique , Ritonavir/usage thérapeutique , Sujet âgé , Association médicamenteuse , Femelle , Humains , Immunosuppresseurs/usage thérapeutique , Transplantation rénale , Receveurs de transplantation
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE